{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:48:20Z","timestamp":1793065700003,"version":"4.5.0"},"reference-count":106,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s13311-022-01188-w","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T11:27:47Z","timestamp":1643282867000},"page":"832-847","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":110,"title":["Stiff-person Syndrome and GAD Antibody-spectrum Disorders: GABAergic Neuronal Excitability, Immunopathogenesis and Update on Antibody Therapies"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7070-1134","authenticated-orcid":false,"given":"Marinos C.","family":"Dalakas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1007\/s13311-022-01188-w_bib1","first-page":"421","article-title":"Progressive fluctuating muscular rigidity and spasm (\"stiff-man\" syndrome); report of a case and some observations in 13 other cases","volume":"31","author":"Moersch","year":"1956","journal-title":"Proc Staff Meet Mayo Clin"},{"issue":"16","key":"10.1007\/s13311-022-01188-w_bib2","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1056\/NEJM198804213181602","article-title":"Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus","volume":"318","author":"Solimena","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-022-01188-w_bib3","doi-asserted-by":"crossref","unstructured":"Dalakas MC, Fujii M, Li M, et al. The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome. Neurology. 2000;55(10):1531\u20135.","DOI":"10.1212\/WNL.55.10.1531"},{"key":"10.1007\/s13311-022-01188-w_bib4","doi-asserted-by":"crossref","unstructured":"Saiz A, Arpa J, Sagasta A, et al. Autoantibodies to glutamic acid decarboxylase in three patients with cerebellar ataxia, late-onset insulin-dependent diabetes mellitus, and polyendocrine autoimmunity. Neurology. 1997;49(4):1026\u201330.","DOI":"10.1212\/WNL.49.4.1026"},{"key":"10.1007\/s13311-022-01188-w_bib5","doi-asserted-by":"crossref","unstructured":"Honnorat J, Saiz A, Giometto B, et al. Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients. Arch Neurol. 2001;58(2):225\u201330.","DOI":"10.1001\/archneur.58.2.225"},{"key":"10.1007\/s13311-022-01188-w_bib6","doi-asserted-by":"crossref","unstructured":"Gresa-Arribas N, Ari\u00f1o H, Mart\u00ednez-Hern\u00e1ndez E, et al. Antibodies to inhibitory synaptic proteins in neurological syndromes associated with glutamic acid decarboxylase autoimmunity. PLoS One. 2015;10(3):e0121364.","DOI":"10.1371\/journal.pone.0121364"},{"issue":"7","key":"10.1007\/s13311-022-01188-w_bib7","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41582-020-0359-x","article-title":"GAD antibodies in neurological disorders - insights and challenges","volume":"16","author":"Graus","year":"2020","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"10.1007\/s13311-022-01188-w_bib8","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/archneurol.2011.991","article-title":"McEvoy KM et al Stiff-Man Syndrome and Variants Clinical Course","volume":"69","author":"McKeon","year":"2012","journal-title":"Treatments, and Outcomes Arch Neurol"},{"key":"10.1007\/s13311-022-01188-w_bib9","doi-asserted-by":"crossref","unstructured":"Tsiortou P, Alexopoulos H, Dalakas MC. GAD antibody-spectrum disorders: Progress in Clinical phenotypes. Immunopathogenesis and Therapeutic interventions Therapeutic Advances in Neurology. 2021;14:17562864211003486. https:\/\/doi.org\/10.1177\/17562864211003486. eCollection 2021.","DOI":"10.1177\/17562864211003486"},{"issue":"8","key":"10.1007\/s13311-022-01188-w_bib10","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJM199302253280805","article-title":"Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer","volume":"328","author":"Folli","year":"1993","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1007\/s13311-022-01188-w_bib11","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1084\/jem.178.6.2219","article-title":"The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of Stiff-Man syndrome with breast cancer","volume":"178","author":"De Camilli","year":"1993","journal-title":"J Exp Med"},{"issue":"2","key":"10.1007\/s13311-022-01188-w_bib12","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0896-6273(00)81165-4","article-title":"Autoimmunity to gephyrin in Stiff-Man syndrome","volume":"26","author":"Butler","year":"2000","journal-title":"Neuron"},{"issue":"3","key":"10.1007\/s13311-022-01188-w_bib13","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1136\/jnnp.47.3.280","article-title":"The stiff-man syndrome: new pathophysiological aspects from abnormal exteroceptive reflexes and the response to clomipramine, clonidine, and tizanidine","volume":"47","author":"Meinck","year":"1984","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1007\/s13311-022-01188-w_bib14","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/ana.410440209","article-title":"Inhibition of gamma-aminobutyric acid synthesis by glutamic acid decarboxylase autoantibodies in stiff-man syndrome","volume":"44","author":"Dinkel","year":"1998","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1007\/s13311-022-01188-w_bib15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/1531-8249(199908)46:2<263::AID-ANA19>3.0.CO;2-0","article-title":"Selective suppression of cerebellar GABAergic transmission by an autoantibody to glutamic acid decarboxylase","volume":"46","author":"Ishida","year":"1999","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1007\/s13311-022-01188-w_bib16","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/jnnp.65.5.633","article-title":"Review of 23 patients affected by the stiff man syndrome: clinical subdivision into stiff trunk (man) syndrome, stiff limb syndrome, and progressive encephalomyelitis with rigidity","volume":"65","author":"Barker","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-022-01188-w_bib17","first-page":"523","article-title":"Autoantibodies and Immunopathogenesis of the Stiff-Person Syndrome; NIH Clinical conference \u201cthe stiff-person syndrome: an autoimmune disorder affecting neurotransmission of g-aminobutyric acid\u201d","volume":"131","author":"Dalakas","year":"1999","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1007\/s13311-022-01188-w_bib18","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1212\/WNL.57.5.780","article-title":"Stiff person syndrome: quantification, specificity, and intrathecal synthesis of GAD65 antibodies","volume":"57","author":"Dalakas","year":"2001","journal-title":"Neurology"},{"issue":"7","key":"10.1007\/s13311-022-01188-w_bib19","doi-asserted-by":"crossref","first-page":"522","DOI":"10.7326\/0003-4819-131-7-199910050-00008","article-title":"The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid","volume":"131","author":"Levy","year":"1999","journal-title":"Ann Intern Med"},{"issue":"Pt 11","key":"10.1007\/s13311-022-01188-w_bib20","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1093\/brain\/123.11.2231","article-title":"Motor cortex excitability in stiff-person syndrome","volume":"123","author":"Sandbrink","year":"2000","journal-title":"Brain"},{"key":"10.1007\/s13311-022-01188-w_bib21","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1212\/WNL.59.3.449","article-title":"Floeter MK Increased brainstem excitability in stiffperson syndrome","volume":"59","author":"Molloy","year":"2002","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01188-w_bib22","doi-asserted-by":"crossref","unstructured":"Levy LM, Levy-Reis I, Fujii M, et al. Brain gamma-aminobutyric acid changes in stiff-person syndrome. Arch Neurol. 2005;62(6):970\u20134.","DOI":"10.1001\/archneur.62.6.970"},{"issue":"11","key":"10.1007\/s13311-022-01188-w_bib23","doi-asserted-by":"crossref","first-page":"7755","DOI":"10.4049\/jimmunol.175.11.7755","article-title":"Analysis of GAD65 autoantibodies in Stiff-Person syndrome patients","volume":"175","author":"Raju","year":"2005","journal-title":"J Immunol"},{"key":"10.1007\/s13311-022-01188-w_bib24","doi-asserted-by":"crossref","unstructured":"Raju R, Rakocevic G, Chen Z, et al. Autoimmunity to GABAA-receptor-associated protein in stiff-person syndrome. Brain. 2006;129(Pt 12):3270\u20136.","DOI":"10.1093\/brain\/awl245"},{"key":"10.1007\/s13311-022-01188-w_bib25","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jneuroim.2015.03.009","article-title":"GAD65 epitope mapping and search for novel autoantibodies in GAD-associated neurological disorders","volume":"281","author":"Fouka","year":"2015","journal-title":"J Neuroimmunol"},{"issue":"11","key":"10.1007\/s13311-022-01188-w_bib26","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1586\/1744666X.2013.845527","article-title":"Immunology of stiff person syndrome and other GAD-associated neurological disorders","volume":"9","author":"Alexopoulos","year":"2013","journal-title":"Expert Rev Clin Immunol"},{"issue":"26","key":"10.1007\/s13311-022-01188-w_bib27","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa01167","article-title":"High-dose intravenous immune globulin for stiff-person syndrome","volume":"345","author":"Dalakas","year":"2001","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1007\/s13311-022-01188-w_bib28","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/ana.25002","article-title":"A double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome","volume":"82","author":"Dalakas","year":"2017","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1007\/s13311-022-01188-w_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12883-018-1232-z","article-title":"Alexopoulos H, Dalakas MC, Quantitative clinical and autoimmune assessments in stiff person syndrome: evidence for a progressive disorder","volume":"19","author":"Rakocevic","year":"2019","journal-title":"BMC Neurol"},{"issue":"Pt 7","key":"10.1007\/s13311-022-01188-w_bib30","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/brain\/123.7.1481","article-title":"Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients","volume":"123","author":"Gultekin","year":"2000","journal-title":"Brain"},{"issue":"4","key":"10.1007\/s13311-022-01188-w_bib31","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-022-01188-w_bib32","doi-asserted-by":"crossref","unstructured":"Malter MP, Helmstaedter C, Urbach H, et al., Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol. 2010;67(4):470\u20138.","DOI":"10.1002\/ana.21917"},{"issue":"2","key":"10.1007\/s13311-022-01188-w_bib33","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s11940-009-0013-9","article-title":"Stiff person syndrome: advances in pathogenesis and therapeutic interventions","volume":"11","author":"Dalakas","year":"2009","journal-title":"Curr Treat Options Neurol"},{"key":"10.1007\/s13311-022-01188-w_bib34","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.expneurol.2013.02.010","article-title":"Progress and stiff challenges in understanding the role of GAD-antibodies in stiff-person syndrome","volume":"247","author":"Dalakas","year":"2013","journal-title":"Exp Neurol"},{"issue":"11","key":"10.1007\/s13311-022-01188-w_bib35","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/j.1365-2362.2010.02340.x","article-title":"A critical update on the immunopathogenesis of Stiff Person Syndrome","volume":"40","author":"Alexopoulos","year":"2010","journal-title":"Eur J Clin Invest"},{"key":"10.1007\/s13311-022-01188-w_bib36","doi-asserted-by":"crossref","unstructured":"McKeon A, Tracy JA. GAD 65 Neurological Autoimmunity Muscle Nerve. 2017;56:15\u201327","DOI":"10.1002\/mus.25565"},{"key":"10.1007\/s13311-022-01188-w_bib37","doi-asserted-by":"crossref","unstructured":"Munoz-Lopetegi A, de Bruijn MAAM, Boukhrissi S, et al. Neurologic syndromes related to anti-GAD65: Clinical and serologic response to treatment. Neurol Neuroimmunol Neuroinflamm. 2020;7:e696","DOI":"10.1212\/NXI.0000000000000696"},{"key":"10.1007\/s13311-022-01188-w_bib38","doi-asserted-by":"crossref","unstructured":"Budhram A, Sechi E, Flanagan EP, et al. Clinical spectrum of high-titre GAD65 antibodies. J Neurol Neurosurg Psychiatry 2021;92:645\u2013654.","DOI":"10.1136\/jnnp-2020-325275"},{"issue":"5","key":"10.1007\/s13311-022-01188-w_bib39","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/mds.10279","article-title":"Stiff man syndrome and related conditions","volume":"17","author":"Meinck","year":"2002","journal-title":"Mov Disord"},{"issue":"6","key":"10.1007\/s13311-022-01188-w_bib40","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1212\/01.wnl.0000237558.83349.d0","article-title":"Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies","volume":"67","author":"Rakocevic","year":"2006","journal-title":"Neurology"},{"issue":"11","key":"10.1007\/s13311-022-01188-w_bib41","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1212\/01.WNL.0000163984.71993.FE","article-title":"A neuropsychological assessment of phobias in patients with stiff person syndrome","volume":"64","author":"Ameli","year":"2005","journal-title":"Neurology"},{"issue":"1","key":"10.1007\/s13311-022-01188-w_bib42","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s13311-019-00796-3","article-title":"Anti-Neuronal Antibodies Within the IVIg Preparations: Importance in Clinical Practice","volume":"17","author":"Dimitriadou","year":"2020","journal-title":"Neurotherapeutics"},{"issue":"12","key":"10.1007\/s13311-022-01188-w_bib43","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.4065\/73.12.1161","article-title":"Radioimmunoassay for glutamic acid decarboxylase (GAD65) autoantibodies as a diagnostic aid for stiff-man syndrome and a correlate of susceptibility to type 1 diabetes mellitus","volume":"73","author":"Walikonis","year":"1998","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1007\/s13311-022-01188-w_bib44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamaneurol.2013.574","article-title":"Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype","volume":"70","author":"McKeon","year":"2013","journal-title":"JAMA Neurol"},{"issue":"22","key":"10.1007\/s13311-022-01188-w_bib45","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1212\/01.wnl.0000436617.40779.65","article-title":"Glycine receptor antibodies in stiff-person syndrome and other GAD-positive CNS disorders","volume":"81","author":"Alexopoulos","year":"2013","journal-title":"Neurology"},{"issue":"12","key":"10.1007\/s13311-022-01188-w_bib46","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1136\/jnnp.2010.229104","article-title":"Antiglycine-receptor encephalomyelitis with rigidity","volume":"82","author":"Mas","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"10.1007\/s13311-022-01188-w_bib47","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1007\/s00415-011-6377-2","article-title":"Glycine receptor antibodies are detected in progressive encephalomyelitis with rigidity and myoclonus (PERM) but not in saccadic oscillations","volume":"259","author":"Iizuka","year":"2012","journal-title":"J Neurol"},{"issue":"3","key":"10.1007\/s13311-022-01188-w_bib48","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/cei.12026","article-title":"Characteristics of in-vitro phenotypes of glutamic acid decarboxylase 65 autoantibodies in high-titre individuals","volume":"171","author":"Cheramy","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"10.1007\/s13311-022-01188-w_bib49","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fnbeh.2015.00078","article-title":"Disease-specific monoclonal antibodies targeting glutamate decarboxylase impair GABAergic neurotransmission and affect motor learning and behavioral functions","volume":"9","author":"Manto","year":"2015","journal-title":"Front Behav Neurosci"},{"issue":"4","key":"10.1007\/s13311-022-01188-w_bib50","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nsmb1228","article-title":"GABA production by glutamic acid decarboxylase is regulated by a dynamic catalytic loop","volume":"14","author":"Fenalti","year":"2007","journal-title":"Nat Struct Mol Biol"},{"issue":"2","key":"10.1007\/s13311-022-01188-w_bib51","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1471-4159.2006.03741.x","article-title":"Evidence that GAD65 mediates increased GABA synthesis during intense neuronal activity in vivo","volume":"97","author":"Patel","year":"2006","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-022-01188-w_bib52","doi-asserted-by":"crossref","unstructured":"Jayakrishnan, B., Hoke DE, Langendorf CG, et al. An analysis of the cross-reactivity of autoantibodies to GAD65 and GAD67 in diabetes. PLoS One. 2011;6(4):e18411.","DOI":"10.1371\/journal.pone.0018411"},{"issue":"6","key":"10.1007\/s13311-022-01188-w_bib53","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1084\/jem.178.6.2097","article-title":"Identification of a dominant epitope of glutamic acid decarboxylase (GAD-65) recognized by autoantibodies in stiff-man syndrome","volume":"178","author":"Butler","year":"1993","journal-title":"J Exp Med"},{"issue":"1","key":"10.1007\/s13311-022-01188-w_bib54","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2249.2002.01960.x","article-title":"Distinct antigenic features of linear epitopes at the N-terminus and C-terminus of 65 kDa glutamic acid decarboxylase (GAD65): implications for autoantigen modification during pathogenesis","volume":"130","author":"Al-Bukhari","year":"2002","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1007\/s13311-022-01188-w_bib55","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1084\/jem.180.2.595","article-title":"Higher autoantibody levels and recognition of a linear NH2-terminal epitope in the autoantigen GAD65, distinguish stiff-man syndrome from insulin-dependent diabetes mellitus","volume":"180","author":"Kim","year":"1994","journal-title":"J Exp Med"},{"issue":"4","key":"10.1007\/s13311-022-01188-w_bib56","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1468-1331.2004.00933.x","article-title":"Antigenic differences between neurological and diabetic patients with anti-glutamic acid decarboxylase antibodies","volume":"12","author":"Vianello","year":"2005","journal-title":"Eur J Neurol"},{"key":"10.1007\/s13311-022-01188-w_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2007.11.077","article-title":"High definition profiling of autoantibodies to glutamic acid decarboxylases GAD65\/GAD67 in stiff-person syndrome","volume":"366","author":"Burbelo","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1007\/s13311-022-01188-w_bib58","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.clim.2005.06.009","article-title":"Humoral autoimmune responses to glutamic acid decarboxylase have similar target epitopes and subclass that show titer-dependent disease association","volume":"117","author":"Piquer","year":"2005","journal-title":"Clin Immunol"},{"key":"10.1007\/s13311-022-01188-w_bib59","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3389\/fneur.2015.00189","article-title":"Serum from a Patient with GAD65 Antibody-Associated Limbic Encephalitis Did Not Alter GABAergic Neurotransmission in Cultured Hippocampal Networks","volume":"6","author":"Stemmler","year":"2015","journal-title":"Front Neurol"},{"key":"10.1007\/s13311-022-01188-w_bib60","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.expneurol.2012.10.013","article-title":"Human Stiff person syndrome IgG-containing high-titer anti-GAD65 autoantibodies induce motor dysfunction in rats","volume":"239","author":"Hansen","year":"2013","journal-title":"Exp Neurol"},{"issue":"9468","key":"10.1007\/s13311-022-01188-w_bib61","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/S0140-6736(05)66376-3","article-title":"Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin","volume":"365","author":"Sommer","year":"2005","journal-title":"Lancet"},{"issue":"8","key":"10.1007\/s13311-022-01188-w_bib62","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s00702-012-0773-3","article-title":"Human IgG directed against amphiphysin induces anxiety behavior in a rat model after intrathecal passive transfer","volume":"119","author":"Geis","year":"2012","journal-title":"J Neural Transm, Vienna"},{"issue":"3","key":"10.1007\/s13311-022-01188-w_bib63","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/ana.25414","article-title":"Abundant glutamic acid decarboxylase (GAD)-reactive B cells in gad-antibody-associated neurological disorders","volume":"85","author":"Thaler","year":"2019","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1007\/s13311-022-01188-w_bib64","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/ana.21123","article-title":"Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases","volume":"61","author":"Manto","year":"2007","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1007\/s13311-022-01188-w_bib65","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1136\/jnnp.2006.091116","article-title":"Selective loss of Purkinje cells in a patient with anti-glutamic acid decarboxylase antibody-associated cerebellar ataxia","volume":"78","author":"Ishida","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-022-01188-w_bib66","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1750-1172-6-3","article-title":"Respective implications of glutamate decarboxylase antibodies in stiff person syndrome and cerebellar ataxia","volume":"6","author":"Manto","year":"2011","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1007\/s13311-022-01188-w_bib67","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/WNL.55.1.46","article-title":"Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy","volume":"55","author":"Peltola","year":"2000","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01188-w_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.seizure.2018.09.009","article-title":"The prevalence of neural antibodies in temporal lobe epilepsy and the clinical characteristics of seropositive patients","volume":"63","author":"Elisak","year":"2018","journal-title":"Seizure"},{"key":"10.1007\/s13311-022-01188-w_bib69","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3389\/fneur.2018.00579","article-title":"Clinical Management of Epilepsy With Glutamic Acid Decarboxylase Antibody Positivity: The Interplay Between Immunotherapy and Anti-epileptic Drugs","volume":"9","author":"Makela","year":"2018","journal-title":"Front Neurol"},{"issue":"1","key":"10.1007\/s13311-022-01188-w_bib70","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1684\/epd.2016.0797","article-title":"Refractory status epilepticus and glutamic acid decarboxylase antibodies in adults: presentation, treatment and outcomes","volume":"18","author":"Khawaja","year":"2016","journal-title":"Epileptic Disord"},{"key":"10.1007\/s13311-022-01188-w_bib71","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jneuroim.2018.06.013","article-title":"Fulminant Anti-GAD antibody encephalitis presenting with status epilepticus requiring aggressive immunosuppression","volume":"323","author":"Triplett","year":"2018","journal-title":"J Neuroimmunol"},{"issue":"5","key":"10.1007\/s13311-022-01188-w_bib72","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/archneurol.2011.2985","article-title":"Autoimmune epilepsy: clinical characteristics and response to immunotherapy","volume":"69","author":"Quek","year":"2012","journal-title":"Arch Neurol"},{"issue":"1\u20132","key":"10.1007\/s13311-022-01188-w_bib73","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jneuroim.2009.04.010","article-title":"Autoantibodies to glutamic acid decarboxylase (GAD) in focal and generalized epilepsy: A study on 233 patients","volume":"211","author":"Errichiello","year":"2009","journal-title":"J Neuroimmunol"},{"issue":"6","key":"10.1007\/s13311-022-01188-w_bib74","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/j.1468-1331.2011.03609.x","article-title":"Prevalence and immunological spectrum of temporal lobe epilepsy with glutamic acid decarboxylase antibodies","volume":"19","author":"Falip","year":"2012","journal-title":"Eur J Neurol"},{"issue":"Suppl. 3","key":"10.1007\/s13311-022-01188-w_bib75","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1528-1167.2011.03031.x","article-title":"Autoantibodies and epilepsy","volume":"52","author":"Bien","year":"2011","journal-title":"Epilepsia"},{"issue":"5","key":"10.1007\/s13311-022-01188-w_bib76","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1111\/epi.16888","article-title":"Musicogenic epilepsy: Expanding the spectrum of glutamic acid decarboxylase 65 neurological autoimmunity","volume":"62","author":"Smith","year":"2021","journal-title":"Epilepsia"},{"issue":"4","key":"10.1007\/s13311-022-01188-w_bib77","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1136\/jnnp.19.4.268","article-title":"Subacute myoclonic spinal neuronitis","volume":"19","author":"Campbell","year":"1956","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-022-01188-w_bib78","doi-asserted-by":"crossref","unstructured":"Hinson SR, Lopez-Chiriboga AS, Bower JH, et al. Glycine receptor modulating antibody predicting treatable stiff-person spectrum disorders. Neurol Neuroimmunol Neuroinflamm. 2018;5(2):e438.","DOI":"10.1212\/NXI.0000000000000438"},{"issue":"Pt 8","key":"10.1007\/s13311-022-01188-w_bib79","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1093\/brain\/awu142","article-title":"Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes","volume":"137","author":"Carvajal-Gonzalez","year":"2014","journal-title":"Brain"},{"key":"10.1007\/s13311-022-01188-w_bib80","doi-asserted-by":"crossref","unstructured":"Tobin WO, Lennon V, Komorowski L, et al. DPPX potassium channel antibody Frequency, clinical accompaniments, and outcomes in 20 patients Neurology 2014;83:1797\u20131803.","DOI":"10.1212\/WNL.0000000000000991"},{"issue":"17","key":"10.1007\/s13311-022-01188-w_bib81","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1212\/WNL.0000000000000372","article-title":"Progressive encephalomyelitis with rigidity and myoclonus: a new variant with DPPX antibodies","volume":"82","author":"Balint","year":"2014","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01188-w_bib82","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11910-008-0009-y","article-title":"Advances in the pathogenesis and treatment of patients with stiff- person syndrome","volume":"8","author":"Dalakas","year":"2008","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"7","key":"10.1007\/s13311-022-01188-w_bib83","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/jnnp.74.7.998","article-title":"Autoantibodies to glutamic acid decarboxylase in downbeat nystagmus","volume":"74","author":"Antonini","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1007\/s13311-022-01188-w_bib84","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ajo.2004.12.052","article-title":"Downbeating nystagmus and muscle spasms in a patient with glutamic-acid decarboxylase antibodies","volume":"140","author":"Ances","year":"2005","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1007\/s13311-022-01188-w_bib85","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.brainres.2006.03.064","article-title":"A rare saccade velocity profile in Stiff-Person Syndrome with cerebellar degeneration","volume":"1093","author":"Zivotofsky","year":"2006","journal-title":"Brain Res"},{"issue":"Pt 6","key":"10.1007\/s13311-022-01188-w_bib86","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1093\/brain\/awh532","article-title":"Vertical nystagmus: clinical facts and hypotheses","volume":"128","author":"Pierrot-Deseilligny","year":"2005","journal-title":"Brain"},{"key":"10.1007\/s13311-022-01188-w_bib87","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jneuroim.2018.01.013","article-title":"Vertical nystagmus associated with glutamic acid decarboxylase antibodies responding to cyclophosphamide","volume":"317","author":"Baizabal-Carvallo","year":"2018","journal-title":"J Neuroimmunol"},{"issue":"6","key":"10.1007\/s13311-022-01188-w_bib88","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.clineuro.2008.03.005","article-title":"Opsoclonus-myoclonus-ataxia syndrome with autoantibodies to glutamic acid decarboxylase","volume":"110","author":"Markakis","year":"2008","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1007\/s13311-022-01188-w_bib89","doi-asserted-by":"crossref","unstructured":"Dalakas MC Treatment of Stiff person syndrome. In: Therapy of Movement Disorders Current Clinical Neurology Reich SG, Factor S (eds) Springer Nature International Publishing Switzerland 2019","DOI":"10.1007\/978-3-319-97897-0_77"},{"issue":"1","key":"10.1007\/s13311-022-01188-w_bib90","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11940-003-0024-x","article-title":"Dalakas MC, Stiff-person Syndrome","volume":"5","author":"Vasconcelos","year":"2003","journal-title":"Curr Treat Options Neurol"},{"key":"10.1007\/s13311-022-01188-w_bib91","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1385\/CRIAI:29:3:255","article-title":"IVIg in patients with anti-GAD antibody associated neurological diseases and patients with inflammatory myopathies: effects on clinicopathologic features and immunoregulatory genes","volume":"29","author":"Dalakas","year":"2005","journal-title":"Clin Review in Allergy & Immunol"},{"key":"10.1007\/s13311-022-01188-w_bib92","doi-asserted-by":"crossref","unstructured":"Dalakas MC. Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-Autoimmunity, evolving Factors on Efficacy and Dosing and Challenges on Stopping chronic IVIg therapy. Neurotherapeutics. 2021. https:\/\/doi.org\/10.1007\/s13311-021-01108-4.","DOI":"10.1007\/s13311-021-01108-4"},{"issue":"12","key":"10.1007\/s13311-022-01188-w_bib93","volume":"100","author":"Aljarallah","year":"2021","journal-title":"Use of subcutaneous immunoglobulin in stiff person syndrome: Case series Medicine (Baltimore)"},{"issue":"7","key":"10.1007\/s13311-022-01188-w_bib94","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/jnnp.2004.051144","article-title":"Treatment of stiff person syndrome with rituximab","volume":"76","author":"Baker","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"10.1007\/s13311-022-01188-w_bib95","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/ncpneuro0901","article-title":"B cells as therapeutic targets in autoimmune neurological disorders","volume":"4","author":"Dalakas","year":"2008","journal-title":"Nat Clin Pract Neurol"},{"key":"10.1007\/s13311-022-01188-w_bib96","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1212\/01.wnl.0000313840.27060.bf","article-title":"Inhibition of B cell functions: Implications for Neurology","volume":"70","author":"Dalakas","year":"2008","journal-title":"Neurology"},{"issue":"1","key":"10.1007\/s13311-022-01188-w_bib97","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/1756285615614812","article-title":"Progressive encephalomyelitis with rigidity and myoclonus (PERM): brucellosis as a possible triggering factor and long-term follow-up therapy with rituximab","volume":"9","author":"Magira","year":"2016","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1007\/s13311-022-01188-w_bib98","doi-asserted-by":"crossref","unstructured":"Kass-Iliyya L, Snowden JA, Thorpe A, et al. Autologous haematopoietic stem cell transplantation for refractory stiff-person syndrome: the UK experience. J Neurol. 2020.","DOI":"10.1007\/s00415-020-10054-8"},{"key":"10.1007\/s13311-022-01188-w_bib99","article-title":"Autologous hematopoietic stem cell transplantation for Stiff Person Spectrum Disorder: A clinical trial","author":"Burt","year":"2020","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01188-w_bib100","article-title":"A Hsct trial in stiff person syndrome: Limited benefits halt enrollment but should be more to come?","author":"Dalakas","year":"2020","journal-title":"Neurology."},{"issue":"8","key":"10.1007\/s13311-022-01188-w_bib101","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s004150050443","article-title":"Plasmapheresis and immunosuppression in stiff-man syndrome with type 1 diabetes: a 2-year study","volume":"246","author":"Hao","year":"1999","journal-title":"J Neurol"},{"key":"10.1007\/s13311-022-01188-w_bib102","doi-asserted-by":"crossref","unstructured":"Dalakas MC. IgG4-mediated neurological autoimmunities: Understanding pathogenicity of IgG4, ineffectiveness of IVIg and long-lasting benefits of anti-B cell therapies. Neurol Neuroimmunol Neuroinflamm. 2022;9:e1116. https:\/\/doi.org\/10.1212\/NXI.0000000000001116.","DOI":"10.1212\/NXI.0000000000001116"},{"key":"10.1007\/s13311-022-01188-w_bib103","unstructured":"Stathopoulos P, Dalakas MC. Evolution of anti-B-cell therapeutics in autoimmune neurological diseases. Neurotherapeutics. In press."},{"key":"10.1007\/s13311-022-01188-w_bib104","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"The Lancet"},{"key":"10.1007\/s13311-022-01188-w_bib105","doi-asserted-by":"crossref","DOI":"10.1177\/1756286421997381","article-title":"The importance of FcRn in neuro-immunotherapies: From IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors","author":"Dalakas","year":"2021","journal-title":"Ther Adv Neurol Disord."},{"key":"10.1007\/s13311-022-01188-w_bib106","doi-asserted-by":"crossref","unstructured":"Lee W-J, Lee S-T, Shin Y-W, et al. Teratoma Removal, Steroid, IVIG, Rituximab and Tocilizumab (T-SIRT) in Anti-NMDAR Encephalitis. Neurotherapeutics. 2020.","DOI":"10.1007\/s13311-020-00921-7"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01188-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-022-01188-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923011066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923011066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01188-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:01:21Z","timestamp":1761807681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923011066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":106,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S1878747923011066"],"URL":"https:\/\/doi.org\/10.1007\/s13311-022-01188-w","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stiff-person Syndrome and GAD Antibody-spectrum Disorders: GABAergic Neuronal Excitability, Immunopathogenesis and Update on Antibody Therapies","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-022-01188-w","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The authors. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}